BTC$62,550.00+1.79%
ETH$1,756.59+3.70%
USDT$0.9991+0.02%
BNB$572.16+2.90%
USDC$0.9999+0.02%
XRP$1.13+4.56%
SOL$82.28+2.20%
TRX$0.3226+1.69%
FIGR_HELOC$1.01-2.89%
HYPE$70.84+7.66%
DOGE$0.0775+5.22%
RAIN$0.0155-0.39%
USDS$0.9998+0.01%
LEO$9.16+0.34%
ZEC$463.09+7.37%
XLM$0.2045+3.83%
BTC$62,550.00+1.79%
ETH$1,756.59+3.70%
USDT$0.9991+0.02%
BNB$572.16+2.90%
USDC$0.9999+0.02%
XRP$1.13+4.56%
SOL$82.28+2.20%
TRX$0.3226+1.69%
FIGR_HELOC$1.01-2.89%
HYPE$70.84+7.66%
DOGE$0.0775+5.22%
RAIN$0.0155-0.39%
USDS$0.9998+0.01%
LEO$9.16+0.34%
ZEC$463.09+7.37%
XLM$0.2045+3.83%
Qualcomm stock climbed over 20% after unveiling its new AI200 and AI250 data center chips and naming Saudi Arabia’s Humain as its first customer for 2026 deployment.
Avidity Biosciences jumped 43% in premarket after Novartis revealed plans to buy the company for $72 per share in a $12 billion deal.
Alliance Resource Partners reported Q3 2025 revenue of $571.4 million and EPS of $0.73, exceeding estimates and tightening its full-year guidance.
Keurig Dr Pepper exceeded expectations with Q3 revenue of $4.31 billion and EPS of $0.54 and raised its full-year net sales guidance.
Revvity reported Q3 2025 revenue of $699 million, slightly below expectations, while adjusted EPS of $1.18 topped forecasts, prompting a full-year guidance raise.
While Target struggles with declining sales, layoffs and a weakened brand strategy, Walmart entrenches its retail dominance.
AMD stock reached an all-time high on strong AI deal momentum and rising analyst targets approaching $300.
Lumen shares rose today following news of a $200 million collaboration with Palantir Technologies to expand AI infrastructure services.
ITW reported Q3 2025 revenue of $4.1 billion and EPS of $2.81, both above expectations.
Inhibrx shares surged over 60% after its cancer drug ozekibart showed a 52% reduction in disease progression, with FDA filing planned for Q2 2026.
Procter & Gamble reported Q1 2026 net sales of $22.4 billion and EPS of $1.95, up 21% year over year.
General Dynamics beat Q3 2025 estimates with revenue of $12.9 billion and EPS of $3.88, supported by strong aerospace demand and solid growth across all segments.
Ventyx shares soared 105% on Phase 2 results demonstrating rapid 80% reduction in key heart disease markers.